spacer
home > epc > winter 2017 > global goals
PUBLICATIONS
European Pharmaceutical Contractor

Global Goals

The achievement of the first patient enrolled (FPI) into a clinical trial is one of the most highly anticipated events of the drug/device development process. The pressure to realise this milestone – whether to meet a corporate target or outpace the competition as the baton passes from one trial to the next – is intense and may precipitate premature study starts, resultant delays and an overall decrease in potential revenue. The fleeting elation at the start of enrolment is quickly abandoned. Anxiety regarding the next and arguably more important milestone – last patient out – builds rapidly. In the rush to achieve FPI, thoughtful study design and reasoned start-up considerations are often neglected to the detriment of the overall development timeline. Re-prioritising study design, in addition to careful consideration of multifactorial influences associated with international studies, will facilitate study start-up and help ensure the ratelimiting, last patient out occurs within expected timeframes.

Right the First Time

Due to the intense pressure to achieve FPI, the industry does not often get protocol design right the first time, resulting in a negative impact to overall timelines and cost. 86% of clinical trials are estimated to experience delays, and 94% of clinical trials are delayed by over one month (1). The protracted timelines associated with the clinical development process directly correlate with increased costs and decreased revenues. The projected costs to bring a new drug to market are currently between $161 million and $2 billion (2). For each day a clinical trial is delayed, up to $8 million in revenue is lost. The cost to implement a substantial amendment is approximately $500,000-$1 million, comprised of internal administrative and investigator expenses, contract change orders or new contracts with service providers, additional drug supply and regulatory fees (2). Thus, careful protocol planning is key to preventing design-related delays, which impede last patient out milestones and generate unnecessary costs associated with protocol amendments.

In addition to the complexity of protocol design, studies are increasingly being conducted in multiple countries and regions in an effort to achieve the required patient numbers to address rare diseases or run large outcome trials, which can create complexities that may not have been anticipated when the protocol was originally conceived. Factoring international considerations into trial design may facilitate a more efficient development process and provide earlier access to medicines for patients (3).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Debbie Elliott is Executive Director of clinical operations at Medpace. She has 20 years of clinical research experience, including over four in Phase 1 research and over 16 in Phase 2/3 clinical trials. She holds a PhD in biological psychology with a minor in neurobiology. Most recently, Debbie directed the global study start-up team within Medpace and currently oversees the proposal and feasibilities team.

Colleen Grawe is Senior Regulatory Submissions Manager at Medpace. She has over 18 years of clinical research experience, including 11 years as a Regulatory Submissions Manager facilitating the start-up of clinical trials as well as seven years as a Clinical Research Associate. She has an Associate of Applied Science in radiologic technology and a Bachelor of Arts in journalism.

Jacqueline Moore is Director of Regulatory Submissions at Medpace and has over 20 years of experience in clinical research, primarily in regulatory affairs, covering all phases and a wide variety of therapeutic indications and investigational products. She has a BSc and PhD in pharmacology from the University of Glasgow, UK.

Gina Steidle is Senior Director of strategic proposals and feasibilities at Medpace. She has over 20 years of experience in pharmaceutical research, including clinical trial management, clinical monitoring management and proposals and feasibilities. She has a Bachelor of Science in nursing from Indiana University School of Nursing, US.


spacer
Debbie Elliott
spacer
spacer
spacer
Colleen Grawe
spacer
spacer
spacer
Jaqueline Moore
spacer
spacer
spacer
Gina Steidle
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Novo Nordisk Pharmatech A/S enters a distribution agreement with Signet Chemical Corporation Pvt. Ltd. for cGMP Quaternary Ammonium Compounds for pharmaceutical and medical device applications

Novo Nordisk Pharmatech A/S has entered into an agreement with Signet Chemical Corporation Pvt. Ltd. for the distribution of their pharmaceutical range of quaternary ammonium compounds (FEF® Quats) to the healthcare industry in India, Bangladesh and Sri Lanka.
More info >>

White Papers

Auto Injectors From Planning To Launch: Preparing for the Overall Development Process

SHL Group

Looking at the rising trend towards self-administration therapies, injectable drug delivery devices, such as pen injectors, auto injectors and needle free injectors, have continued to show significant growth in the international market.
More info >>

 
Industry Events

SMi’s 9th Annual Biosimilars & Biobetters Conference

25-27 September 2018, Copthorne Tara Hotel, London, UK

Following the success of our previous events in both London and the US, Biosimilars and Biobetters UK 2018, SMi deliver a stellar speaker line-up and bring together a global audience of biosimilar experts to discuss the latest developments and future of the rapidly evolving and expanding biosimilars market.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement